154 related articles for article (PubMed ID: 37775668)
21. Tumor cell lysates as immunogenic sources for cancer vaccine design.
González FE; Gleisner A; Falcón-Beas F; Osorio F; López MN; Salazar-Onfray F
Hum Vaccin Immunother; 2014; 10(11):3261-9. PubMed ID: 25625929
[TBL] [Abstract][Full Text] [Related]
22. Tumor cells endowed with professional antigen-presenting cell functions prime PBLs to generate antitumor CTLs.
Chiozzini C; Olivetta E; Sanchez M; Arenaccio C; Ferrantelli F; Leone P; Federico M
J Mol Med (Berl); 2019 Aug; 97(8):1139-1153. PubMed ID: 31161312
[TBL] [Abstract][Full Text] [Related]
23. Presentation of native TROP-2 tumor antigens to human cytotoxic T lymphocytes by engineered antigen-presenting cells.
Mangino G; Grazia Capri M; Barnaba V; Alberti S
Int J Cancer; 2002 Oct; 101(4):353-9. PubMed ID: 12209960
[TBL] [Abstract][Full Text] [Related]
24. Exosomes as a tumor vaccine: enhancing potency through direct loading of antigenic peptides.
Hsu DH; Paz P; Villaflor G; Rivas A; Mehta-Damani A; Angevin E; Zitvogel L; Le Pecq JB
J Immunother; 2003; 26(5):440-50. PubMed ID: 12973033
[TBL] [Abstract][Full Text] [Related]
25. Priming and activation of human ovarian and breast cancer-specific CD8+ T cells by polyvalent Listeria monocytogenes-based vaccines.
Sinnathamby G; Lauer P; Zerfass J; Hanson B; Karabudak A; Krakover J; Secord AA; Clay TM; Morse MA; Dubensky TW; Brockstedt DG; Philip R; Giedlin M
J Immunother; 2009 Oct; 32(8):856-69. PubMed ID: 19752748
[TBL] [Abstract][Full Text] [Related]
26. Cellular vaccines.
Bartholeyns J; Romet-Lemonne JL; Chokri M; Buyse M; Velu T; Bruyns C; Van de Winkel JJ; Heeney J; Koopman G; Malmsten M; De Groote D; Monsigny M; Midoux P; Alarcon B
Res Immunol; 1998; 149(7-8):647-9. PubMed ID: 9851517
[TBL] [Abstract][Full Text] [Related]
27. MHC class I-presented tumor antigens identified in ovarian cancer by immunoproteomic analysis are targets for T-cell responses against breast and ovarian cancer.
Morse MA; Secord AA; Blackwell K; Hobeika AC; Sinnathamby G; Osada T; Hafner J; Philip M; Clay TM; Lyerly HK; Philip R
Clin Cancer Res; 2011 May; 17(10):3408-19. PubMed ID: 21300761
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic gene modified cell based cancer vaccines.
Kozłowska A; Mackiewicz J; Mackiewicz A
Gene; 2013 Aug; 525(2):200-7. PubMed ID: 23566846
[TBL] [Abstract][Full Text] [Related]
29. Treatment of hepatocellular carcinoma with the cellular tumor vaccines generated by in vitro modification of tumor cells with non gene transfer approaches.
Wu S; Ma J; Che X; Liu Y; Wang H; Zhao J; Shen F; Xie T; Trojan J; Wu M; Guo Y
Adv Exp Med Biol; 1998; 451():283-93. PubMed ID: 10026886
[TBL] [Abstract][Full Text] [Related]
30. MHC class II presentation of endogenous tumor antigen by cellular vaccines depends on the endocytic pathway but not H2-M.
Qi L; Ostrand-Rosenberg S
Traffic; 2000 Feb; 1(2):152-60. PubMed ID: 11208095
[TBL] [Abstract][Full Text] [Related]
31. DNA vaccine for cancer immunotherapy.
Yang B; Jeang J; Yang A; Wu TC; Hung CF
Hum Vaccin Immunother; 2014; 10(11):3153-64. PubMed ID: 25625927
[TBL] [Abstract][Full Text] [Related]
32. Nonreplicating recombinant vaccinia virus expressing CD40 ligand enhances APC capacity to stimulate specific CD4+ and CD8+ T cell responses.
Feder-Mengus C; Schultz-Thater E; Oertli D; Marti WR; Heberer M; Spagnoli GC; Zajac P
Hum Gene Ther; 2005 Mar; 16(3):348-60. PubMed ID: 15812230
[TBL] [Abstract][Full Text] [Related]
33. Synergistic effect of dual targeting vaccine adjuvant with aminated β-glucan and CpG-oligodeoxynucleotides for both humoral and cellular immune responses.
Jin JW; Tang SQ; Rong MZ; Zhang MQ
Acta Biomater; 2018 Sep; 78():211-223. PubMed ID: 30098441
[TBL] [Abstract][Full Text] [Related]
34. Regulatory T-cell response and tumor vaccine-induced cytotoxic T lymphocytes in human melanoma.
Chakraborty NG; Chattopadhyay S; Mehrotra S; Chhabra A; Mukherji B
Hum Immunol; 2004 Aug; 65(8):794-802. PubMed ID: 15336780
[TBL] [Abstract][Full Text] [Related]
35. Relationship of vaccine efficacy to the kinetics of DC and T-cell responses induced by PLG-based cancer vaccines.
Ali OA; Doherty E; Mooney DJ; Emerich D
Biomatter; 2011; 1(1):66-75. PubMed ID: 23507728
[TBL] [Abstract][Full Text] [Related]
36. A new TLR2 agonist promotes cross-presentation by mouse and human antigen presenting cells.
Santone M; Aprea S; Wu TY; Cooke MP; Mbow ML; Valiante NM; Rush JS; Dougan S; Avalos A; Ploegh H; De Gregorio E; Buonsanti C; D'Oro U
Hum Vaccin Immunother; 2015; 11(8):2038-50. PubMed ID: 26024409
[TBL] [Abstract][Full Text] [Related]
37. Effective therapeutic anticancer vaccines based on precision guiding of cytolytic T lymphocytes.
Melief CJ; Van Der Burg SH; Toes RE; Ossendorp F; Offringa R
Immunol Rev; 2002 Oct; 188():177-82. PubMed ID: 12445291
[TBL] [Abstract][Full Text] [Related]
38. Functional characterization of biodegradable nanoparticles as antigen delivery system.
Petrizzo A; Conte C; Tagliamonte M; Napolitano M; Bifulco K; Carriero V; De Stradis A; Tornesello ML; Buonaguro FM; Quaglia F; Buonaguro L
J Exp Clin Cancer Res; 2015 Oct; 34():114. PubMed ID: 26444005
[TBL] [Abstract][Full Text] [Related]
39. Failure of cancer vaccines: the significant limitations of this approach to immunotherapy.
Bodey B; Bodey B; Siegel SE; Kaiser HE
Anticancer Res; 2000; 20(4):2665-76. PubMed ID: 10953341
[TBL] [Abstract][Full Text] [Related]
40. Defining HLA-II Ligand Processing and Binding Rules with Mass Spectrometry Enhances Cancer Epitope Prediction.
Abelin JG; Harjanto D; Malloy M; Suri P; Colson T; Goulding SP; Creech AL; Serrano LR; Nasir G; Nasrullah Y; McGann CD; Velez D; Ting YS; Poran A; Rothenberg DA; Chhangawala S; Rubinsteyn A; Hammerbacher J; Gaynor RB; Fritsch EF; Greshock J; Oslund RC; Barthelme D; Addona TA; Arieta CM; Rooney MS
Immunity; 2019 Oct; 51(4):766-779.e17. PubMed ID: 31495665
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
